Parathyroid carcinoma: 50-year experience at The Cleveland Clinic Foundation

Hakaim, Albert G.; Esselstyn, Caldwell B.

doi:10.3949/ccjm.60.4.331

Cited by 80 publications

(52 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, therapies such as calcimimetic agents that focus on decreasing PTH secretion may better prevent complications and improve survival in patients with no curable disease. 34 Our 5-year survival rate of 85% was consistent with that of previous reports, 6 but our 10-year survival is somewhat higher at 77%. 32 Because the data are derived from patients diagnosed in the past 22 years only, the difference in long-term survival seen in this series compared with others' and our previous series may relate to improvements in overall general supportive medical care and prevention of fatal hypercalcemia.…”

Section: Discussionsupporting

confidence: 91%

Parathyroid carcinoma: A 22‐year experience

et al. 2004

View full text Add to dashboard Cite

Purpose. Because parathyroid carcinoma is rare, clear consensus is not available regarding the optimal management of patients with this condition. Treatment strategies generally derive from clinical and anecdotal experiences. We report our experience with this entity.Methods. We included all patients with parathyroid carcinoma seen at The University of Texas M. D. Anderson Cancer Center since January 1, 1980. The medical records and pathology specimens were reviewed and verified in all cases.

show abstract

Section: Discussionsupporting

confidence: 91%

Parathyroid carcinoma: A 22‐year experience

et al. 2004

View full text Add to dashboard Cite

show abstract

“…P arathyroid cancer is a rare disease, accounting for <1% of all cases of hyperparathyroidism [1][2][3] and for only 0.005% of all cancers. 4 Most parathyroid cancers secrete parathyroid hormone (PTH) and cause hypercalcemia.…”

mentioning

confidence: 99%

Trends in the incidence and treatment of parathyroid cancer in the United States

Lee

Jarosek

Virnig

et al. 2007

Cancer

268

235

View full text Add to dashboard Cite

BACKGROUND.Parathyroid cancer is a rare cause of hyperparathyroidism. The objectives of this study were to determine the patterns of disease, treatment trends, and outcomes among patients with parathyroid cancer by using a population‐based data source.METHODS.Surveillance, Epidemiology, and End Results (SEER) cancer registry data were used to identify patients who were diagnosed with parathyroid cancer from 1988 through 2003. To assess whether the incidence rate, treatment, tumor size, and cancer stage changed over time, the Cochrane‐Armitage trend test was used, and Cox proportional‐hazards modeling was used to identify the factors associated with an improved overall survival rate.RESULTS.From 1988 through 2003, 224 patients with parathyroid cancer were reported in the SEER data. Over that 16‐year study period, the incidence of parathyroid cancer increased by 60% (1988–1991, 3.58 per 10,000,000 population; 2000–2003, 5.73 per 10,000,000 population). Most patients (96%) underwent surgery (parathyroidectomy, 78.6% of patients; en bloc resection, 12.5% of patients; other, 4.9% of patients). The rate of surgical treatment increased significantly during the study period. The 10‐year all‐cause mortality rate was 33.2%, and the 10‐year cancer‐related mortality rate was 12.4%. Patient age (P < .0001), sex (P = .0106), the presence of distant metastases at diagnosis (P = .0004), and the year of diagnosis (P = .0287) were associated significantly with the overall survival rate. Tumor size, lymph node status, and type of surgery were not associated significantly with the overall survival rate.CONCLUSIONS.Although parathyroid cancer is rare, the incidence increased significantly in the United States from 1988 through 2003. Young age, female gender, recent year of diagnosis, and absence of distant metastases were associated significantly with an improved survival rate. Cancer 2007. © 2007 American Cancer Society.

show abstract

“…Our 5-year survival rate of 85% was consistent with the rates from previous reports, but the 10-year survival rate was somewhat higher at 77%. 3,26 Because the data were derived only from patients who were diagnosed in the past 20 years, the difference in long-term survival may relate to improvements in supportive medical care in general and, more specifically, in the control of hypercalcemia.…”

Section: Survivalmentioning

confidence: 99%

“…[1][2][3][4] de Quevain 5 described this entity first in 1904 in a patient who presented with a nonfunctioning lesion. Subsequently, in 1933, Sainton and Millot 6 described the first functioning parathyroid carcinoma.…”

mentioning

confidence: 99%

Parathyroid carcinoma: Evaluation and interdisciplinary management

Clayman

González

El‐Naggar

et al. 2004

Cancer

112

View full text Add to dashboard Cite

BACKGROUNDA review of recent reports found a distinct clinical behavior pattern in the rare clinical entity of parathyroid carcinoma, although to the authors' knowledge information on oncogenetic changes, prognostic factors, and the potential benefits of adjuvant therapy remain fragmented and scarce. In this report, a composite review of the literature and The University of Texas M. D. Anderson Cancer Center (M. D. Anderson) experience are presented using the presentation of a patient to illustrate critical issues in the evaluation and interdisciplinary management of patients who are afflicted with this disease.METHODSThe current study reflects a retrospective case review of patients who were diagnosed with parathyroid carcinoma, treated, and followed at M. D. Anderson from 1983 to 2002. To assure standardization of pathologic diagnosis as well as evaluations and interdisciplinary management, the investigators reviewed all cases using predetermined criteria within their specialties.RESULTSIt is interesting to note that M. D. Anderson data showed classic pathologic features that were not always present in all parathyroid carcinomas (at most, some features were noted in 37% of patients). Other results of interest indicated local recurrence rates that appeared lower if adjuvant radiation was applied after initial surgery, independent of the type of surgery or disease stage. In the authors' experience, 70% of patient's tumors exhibited local invasion, although their 5‐year survival rate of 85% was consistent with that reported previously, and their 10‐year survival rate was somewhat higher at 77%.CONCLUSIONSParathyroid carcinoma is a rare clinical entity that requires interdisciplinary evaluation and management. Comprehensive surgical excision of parathyroid carcinomas with verification of normalization of intraoperative parathyroid hormone levels should be sought. Cancer 2004;100:900–5. © 2004 American Cancer Society.

show abstract

Parathyroid carcinoma: 50-year experience at The Cleveland Clinic Foundation

Cited by 80 publications

References 0 publications

Parathyroid carcinoma: A 22‐year experience

Parathyroid carcinoma: A 22‐year experience

Trends in the incidence and treatment of parathyroid cancer in the United States

Parathyroid carcinoma: Evaluation and interdisciplinary management

Contact Info

Product

Resources

About